Critical issues in the economic evaluation of interventions against communicable diseases

Acta Tropica

Volumn 78, Issue 3, 2001, Pages 191-206

  Hutubessy, Raymond C W ^a   Bendib, Lydia M ^a   Evans, David B ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Communicable disease control; Cost effectiveness; Developing countries; Economic evaluation; Generalisability; Review

Indexed keywords

DISEASE CONTROL; ECONOMIC ANALYSIS; METHODOLOGY; POLICY MAKING;

COMMUNICABLE DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DEVELOPED COUNTRY; ECONOMIC EVALUATION; HEALTH CARE; HEALTH CARE POLICY; REVIEW;

COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; COST-BENEFIT ANALYSIS; DECISION MAKING; DEVELOPING COUNTRIES; DISEASE TRANSMISSION; HUMANS; PUBLIC HEALTH;

EID: 0035970464     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-706X(00)00176-5     Document Type: Review

References (117)

1. Economic analysis in randomized control trials
2. Valuing outcomes in health care: A comparison of willingness to pay and quality-adjusted life-years
3. Willingness to pay as a measure of health benefits
4. The economic rationale for investing in nutrition in developing countries
5. What do patients value? Willingness to pay for ultrasound in normal pregnancy
6. The cost-effectiveness of permethrin impregnated bednets in preventing child mortality in Kassena-Nankana district of Northern GHA
7. Willingness to pay and the valuation of programmes for the prevention and control of influenza
8. Methodologic evaluation of the radiology cost-effectiveness literature
9. Economic analyses of radiological procedures: A methodoligical evaluation of the medical literature
10. Use of contingent valuation to place a monetary value on pharmacy services: An overview and review of the literature
11. The Oregon experiment: The role of cost-benefit analysis in the allocation of Medicaid funds
12. A cost-effectiveness analysis of vaccination strategies against N. meningitidis meningitis in sub-Saharan African countries
13. Immunization programs and their costs
14. Handling uncertainty when performing economic evaluation of healthcare interventions
15. Economic analysis at the global level: A resource requirement model for HIV prevention in developing countries
16. Extrapolation of cost-effectiveness information to local settings
17. Rebound mortality and the cost-effectiveness of malaria control: Potential impact of increased mortality in late childhood following the introduction of insecticide treated nets
18. Health care contingent valuation studies: A review and classification of the literature
19. Valuing the benefits of publicly-provided health care: Does 'ability to pay' preclude the use of 'willingness to pay'?
20. Guidelines for authors and peer reviewers of economic submissions to the BMJ
21. Cost-effectiveness league tables: More harm than good?
22. Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid?
23. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy
24. Health care CBA and CEA from 1991 to 1996: An updated bibliography
25. The cost effectiveness of mass drug therapy for intestinal helminths
26. The application of economic evaluation techniques in the health sector: The state of the art
27. Should governments subsidize the use of insecticide-impregnated mosquito nets in Africa? Implications of a cost-effectiveness analysis
28. The affordability of antiretroviral therapy in developing countries: What policymakers need to know
29. Review of published cost-effectiveness studies on tuberculosis treatment programmes
30. Willingness to pay. What's in a name?
31. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania
32. The evidence base on the cost-effectiveness of malaria control measures in Africa
33. Cost-effectiveness of malaria control in sub-Saharan Africa
34. Evaluating the cost-effectiveness of clinical and public health measures
35. Cost-effectiveness analysis of humanitarian relief interventions: Visceral leishmaniasis treatment in the Sudan
36. Association of early childhood diarrhea and cryptosporidiosis with impaired physical fitness and cognitive function four-seven years later in a poor urban community in northeast BRA
37. Economic considerations for helminth control
38. Controlling schistosomiasis: The cost-effectiveness of alternative delivery strategies
39. Malaria epidemiology and economics: The effect of delayed immune acquisition on the cost-effectiveness of insecticide-treated bednets
40. Economic analysis in health care: An introduction to the methodology with an emphasis on radiation therapy
41. Economic evaluations in the critical care literature: Do they help us improve the efficiency of our unit?
42. A cost-effectiveness analysis of anthelminthic intervention for community control of soil-transmitted helminth infection: Levamisole and Ascaris lumbricoides
43. An overview of the effectiveness and efficiency of HIV prevention programs
44. Is vaccination against hepatitis B efficient? A review of world literature
45. Methodological quality of economic modelling studies. A case study with hepatitis B vaccines
46. An exercise on the feasibility of carrying out secondary economic analyses
47. Economic evaluation in health care: Is there a role for cost-benefit analysis?
48. Willingness to pay for antihypertensive therapy - Results of a Swedish pilot study
49. Economics, pharmaceuticals, and pharmacoeconomics
50. Cost-effectiveness of chemotherapy for sputum smear-positive pulmonary tuberculosis in Malawi, Mozambique and Tanzania
51. Economic analysis in health care: An introduction to the methodology with an emphasis on radiation therapy
52. Hepatitis B
53. Willingness to pay for reductions in angina pectoris attacks
54. Economic evaluation in schistosomiasis: Using the Delphi technique to assess effectiveness
55. Economic evaluation in schistosomiasis: Valuation of health states preferences. A research note
56. The contingent valuation method in health care
57. Insecticide-treated bednets and curtains for malaria control (Cochrane Review)
58. Panel on cost-effectiveness in health and medicine recommendations: Identifying costs
59. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa
60. The generalisability of pharmacoeconomic studies
61. Recent advances in the methods of cost-benefit analysis in healthcare. Matching the art to the science
62. Cost-benefit and cost-effectiveness analysis of vaccine policy
63. Policy analysis of the use of hepatitis B, haemophilus influenzae type b, streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules
64. Economic evaluation of malaria control in Africa-Willingness to pay for treated mosquito nets in Surat, India - Towards interventions to improve malaria management in the private sector
65. Modeling the impact of global tuberculosis control strategies
66. Tuberculosis
67. The global burden of disease in 1990: Summary results, sensitivity analysis and future directions
68. Development of WHO guidelines on generalized cost-effectiveness analysis
69. The willingness to pay for in vitro fertilization: A pilot study using contingent valuation
70. Cost-effectiveness and cost-benefit in the prevention of mother-to-child transmission of HIV in developing countries
71. A healthy body and a healthy mind?: The relationship between ill-health and cognitive function in school-age children
72. Trichuris trichiura infection and mental development in children
73. Compliance and absenteeism in school children: Implications for helminth control
74. Moderate to heavy infections of Trichuris trichiura affect cognitive function in Jamaican school children
75. Parasitic helminth infection and cognitive function in school children
76. Evidence for an improvement in cognitive function following treatment of Schistosoma japonicum infection in Chinese primary schoolchildren
77. Willingness to pay for community-based ivermectin distribution: A study of three onchocerciasis-endemic communities in Nigeria
78. Valuing health care benefits in money terms
79. Behavioral issues in the efficacy versus effectiveness of pharmacologic agents in the prevention of cardiovascular disease
80. Cost-effectiveness analysis of alternative treatments of African gambiense trypanosomiasis in Uganda
81. Efficacy and effectiveness issues in the NIDA Cooperative Agreement: Interventions for out-of-treatment drug users
82. Is there a need for standarization of methods in economic evaluations of medicine?
83. The standards debate. What have we learned?
84. Modeling the impact and cost-effectiveness of HIV prevention efforts
85. Evaluation of pharmacoeconomic studies: Utilization of a checklist
86. Principles of economic analysis of health care technology
87. Evidence for an association between hookworm infection and cognitive function in Indonesian school children
88. Pharmacoeconomics: State of the art in 1997
89. Guidelines for pharmacoeconomics studies. Recommendations from the panel on cost effectiveness in health and medicine
90. Recommendations for reporting cost-effectiveness analyses
91. Affordability, cost-effectiveness and efficiency of primary health care: The Bamako Initiative experience in Benin and Guinea
92. Physical fitness, growth and appetite of Kenyan school boys with hookworm, Trichuris trichiura and Ascaris lumbricoides infections are improved four months after a single dose of albendazole
93. Health, nutrition and economic development
94. Epidemiology of tuberculosis
95. The association of the risk of tuberculosis infection with age
96. Enormous variation in the cost-effectiveness of prevention: Implications for public policy
97. Five-hundred life-saving interventions and their cost-effectiveness
98. Oregon's Medicaid ranking and cost-effectiveness: Is there any relationship?
99. Discounting the health effects for medical decisions
100. Economic evaluation of communicable disease interventions in developing countries: A critical review of the published literature
101. Economic evaluation of parasitic diseases: A critique of the internal and external validity of published studies
102. Poverty and mortality among the elderly: Measurement of performance in 33 countries 1960-1992
103. Antiretroviral drugs as a public health intervention for pregnant HIV- infected women in rural South Africa: An issue of cost-effectiveness and capacity